- Previous Close
6.00 - Open
6.00 - Bid 5.16 x 100
- Ask 6.88 x 100
- Day's Range
5.98 - 6.17 - 52 Week Range
4.31 - 7.30 - Volume
8,960 - Avg. Volume
8,470 - Market Cap (intraday)
8.894M - Beta (5Y Monthly) 1.42
- PE Ratio (TTM)
-- - EPS (TTM)
-1.81 - Earnings Date Nov 18, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.
www.precipiodx.com51
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: PRPO
View More
Performance Overview: PRPO
Trailing total returns as of 11/20/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PRPO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PRPO
View MoreValuation Measures
Market Cap
8.89M
Enterprise Value
9.12M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.50
Price/Book (mrq)
0.74
Enterprise Value/Revenue
0.52
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-22.90%
Return on Assets (ttm)
-18.98%
Return on Equity (ttm)
-29.22%
Revenue (ttm)
16.72M
Net Income Avi to Common (ttm)
-3.83M
Diluted EPS (ttm)
-1.81
Balance Sheet and Cash Flow
Total Cash (mrq)
1.28M
Total Debt/Equity (mrq)
9.66%
Levered Free Cash Flow (ttm)
-894.75k
Research Analysis: PRPO
View MoreCompany Insights: PRPO
PRPO does not have Company Insights